Response to Comments: MolDX: HLA-DQB1 0602 Testing for Narcolepsy

This document (A54813) is a response to comments regarding MolDX HLA-DQB1*0602 testing for narcolepsy and records the comment (2015-10-13 to 2015-11-27) and notice (2015-12-31 to 2016-02-14) periods; the associated Local Coverage Determination becomes final on 2016-02-15. The response document does not itself state clinical coverage indications, limitations, documentation requirements, or frequency limits; those should be obtained from the final LCD.

"Document is a response to provider comments on MolDX HLA-DQB1 0602 testing for narcolepsy; comment period 2015-10-13 to 2015-11-27; notice period 2015-12-31 to 2016-02-14; LCD becomes final 2016-02..."

Sign up to see full coverage criteria, indications, and limitations.